Copyright © 2002 by the European Society of Cardiology.
Short-term effects of atorvastatin on C-reactive protein
a Institute of Clinical Chemistry and Hematology, Kantonsspital, St. Gallen, Switzerland
b Ospedale della Beata Vergine, Mendrisio, Switzerland
revised August 13, 2001; accepted August 15, 2001
Abstract
Aim To study the short-term effect of atorvastatin on C-reactive protein (CRP) in patients with or at risk for coronary heart disease.
Methods and Results One hundred and fifty-five randomly selected patients from the SWiss Intervention Trial for lowering CHolesterol (SWITCH) were assessed for high sensitivity CRP, total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides at baseline, and after 1 and 3 months of treatment with atorvastatin at various doses to reach pre-defined lipid target values. The median decrease of cholesterol was 28% after 1 month and 35% after 3 months. LDL-cholesterol was decreased by 37% and 45%, HDL-cholesterol was increased by 7% and 8%, respectively. Patients with a low CRP baseline concentration (lowest quartile <1·34mg.l–1) displayed no significant change, whereas patients in the other quartiles showed a significant decrease, of 22% to 40% (P -value <0·05 to <0·001) at 1 month and of 32% to 36% after 3 months compared to baseline. The decrease in CRP lowering was thus fully established by 1 month and this response was independent of lipid and lipoprotein changes as well as atorvastatin doses.
Conclusion Atorvastatin significantly decreases CRP concentrations after 4 weeks of therapy. These results may be important with respect to the early benefit of statin therapy.
Key Words: High sensitivity CRP, atorvastatin, statins, acute coronary syndromes
f1 Correspondence: Prof. Dr W. F. Riesen, Institute of Clinical Chemistry and Hematology, Kantonsspital, 9007 St. Gallen, Switzerland.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Montalescot, H. Drexler, R. Gallo, T. Pearson, M. Thoenes, and D. L. Bhatt Effect of irbesartan and enalapril in non-ST elevation acute coronary syndrome: results of the randomized, double-blind ARCHIPELAGO study Eur. Heart J., November 2, 2009; 30(22): 2733 - 2741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Aydin, M. Ugurlucan, F. Gungor, S. Ziyade, B. Inan, M. Banach, Y. Kalko, and T. Yasar Effects of Atorvastatin on Vascular Intimal Hyperplasia: An Experimental Rodent Model Angiology, June 1, 2009; 60(3): 370 - 377. [Abstract] [PDF]
|
|
|
|
 |
|
 E. R. Mohler III, C. M. Ballantyne, M. H. Davidson, M. Hanefeld, L. M. Ruilope, J. L. Johnson, A. Zalewski, and for the Darapladib Investigators The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent: The Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study J. Am. Coll. Cardiol., April 29, 2008; 51(17): 1632 - 1641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kinlay Low-Density Lipoprotein-Dependent and -Independent Effects of Cholesterol-Lowering Therapies on C-Reactive Protein: A Meta-Analysis J. Am. Coll. Cardiol., May 22, 2007; 49(20): 2003 - 2009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Save, N. Patil, N. Moulik, and G. Rajadhyaksha Effect of Atorvastatin on Type 2 Diabetic Dyslipidemia Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2006; 11(4): 262 - 270. [Abstract] [PDF]
|
|
|
|
 |
|
 S. B. Kritchevsky, M. Cesari, and M. Pahor Inflammatory markers and cardiovascular health in older adults Cardiovasc Res, May 1, 2005; 66(2): 265 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A.H. Stewart, H. D. White, A. C. Kirby, S. R. Heritier, R. J. Simes, P. J. Nestel, M. J. West, D. M. Colquhoun, A. M. Tonkin, and for the Long-Term Intervention With Pravastatin in White Blood Cell Count Predicts Reduction in Coronary Heart Disease Mortality With Pravastatin Circulation, April 12, 2005; 111(14): 1756 - 1762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. M. Campese, M. K. Nadim, and M. Epstein Are 3-Hydroxy-3-Methylglutaryl-CoA Reductase Inhibitors Renoprotective? J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S11 - S17. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Li, S.-P. Zhao, D.-q. Peng, Z.-m. Xu, and H.-n. Zhou Early Effect of Pravastatin on Serum Soluble CD40L, Matrix Metalloproteinase-9, and C-Reactive Protein in Patients with Acute Myocardial Infarction Clin. Chem., September 1, 2004; 50(9): 1696 - 1699. [Full Text] [PDF]
|
|
|
|
|
|
B. Horvath, L. Szapary, Z. Marton, T. Alexy, G. Kesmarky, and K. Toth Short-term effects of atorvastatin on haemorheologic parameters, platelet aggregation and endothelium dysfunction in patients with hypercholesterolaemia Eur. Heart J., January 1, 2004; 25(1): 96 - 96. [Full Text] [PDF]
|
|
|
|
 |
|
 J. M Backes, P. A Howard, and P. M Moriarty Role of C-Reactive Protein in Cardiovascular Disease Ann. Pharmacother., January 1, 2004; 38(1): 110 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Balk, J. Lau, L. C. Goudas, H. S. Jordan, B. Kupelnick, L. U. Kim, and R. H. Karas Effects of Statins on Nonlipid Serum Markers Associated with Cardiovascular Disease: A Systematic Review Ann Intern Med, October 21, 2003; 139(8): 670 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kluft Is C-reactive protein an additional, surrogate end-point for statin treatment? Eur. Heart J., May 2, 2002; 23(10): 761 - 764. [Full Text] [PDF]
|
|